UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-40908 MiNK Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-2142067 (St ...

Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKTGKCC, LLC joins as a new investor with Katie Chudnovsky appointed as a Board Observer NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediat ...

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 14, 2024. MiNK executives will host a conference call and webcast ...

MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid modelsMiNK-215 exhibits potent anti-tumor activity through multiple mechanisms including immune activation NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today ann ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40908 MiNK Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Securities registered pursuant to Section 12(b) ...

Zack Armen - Head, Investor Relations Jennifer Buell - President and Chief Executive Officer Marc Van Dijk - Chief Scientific Officer Christine Klaskin - Principal Financial and Accounting Officer Operator Thank you, Lisa, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. Company Participants Emily Bodnar - H.C. Wainwright Jack Allen - Baird Mayank Mamtani - B. Reilly Securities I would now like to turn the conference over to Zack Armen, H ...

EXHIBIT 99.1 MiNK Reports Fourth Quarter and Year-End 2023 Results NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune- mediated diseases, today announced results for the fourth quarter and full-year 2023. MiNK executives will host a conference call and webcast a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-40908 MiNK Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-2142067 ...

Zack Armen â Head, Investor Relations Jennifer Buell - President and Chief Executive Officer Marc Van Dijk - Chief Scientific Officer Christine Klaskin â Principal Financial and Accounting Officer Good morning, and welcome to MiNK Therapeutics' Third Quarter 2023 Conference Call and Webcast. All participants will be in a listen-only mode until the question-and-answer session. Please note this event is being recorded. If anyone has any objections, you may now disconnect at this time. I'd like to remind you t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-40908 MiNK Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-2142067 (State or other jurisdiction of incorporation or organization) 149 Fifth Avenue Suite 500 New ...